Candel Therapeutics Inc [CADL] stock is trading at $8.20, down -0.73%. An important factor to consider is whether the stock is rising or falling in short-term value. The CADL shares have gain 3.67% over the last week, with a monthly amount glided 5.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Candel Therapeutics Inc [NASDAQ: CADL] stock has seen the most recent analyst activity on February 20, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $25. Previously, Canaccord Genuity started tracking the stock with Buy rating on February 19, 2025, and set its price target to $20. On February 07, 2025, BofA Securities initiated with a Buy rating and assigned a price target of $15 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $11 on December 02, 2022. BMO Capital Markets initiated its recommendation with a Outperform and recommended $18 as its price target on November 19, 2021. UBS started tracking with a Buy rating for this stock on August 23, 2021, and assigned it a price target of $9. In a note dated August 23, 2021, Jefferies initiated an Buy rating and provided a target price of $22 on this stock.
Candel Therapeutics Inc [CADL] stock has fluctuated between $1.34 and $14.60 over the past year. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $8.20 at the most recent close of the market.
Analyzing the CADL fundamentals
Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -20.02%, Pretax Profit Margin comes in at -29.39%, and Net Profit Margin reading is -29.39%. To continue investigating profitability, this company’s Return on Assets is posted at -2.43, Equity is 32.1 and Total Capital is -5.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.86 points at the first support level, and at 7.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.57, and for the 2nd resistance point, it is at 8.95.
Ratios To Look Out For
For context, Candel Therapeutics Inc’s Current Ratio is 1.18. On the other hand, the Quick Ratio is 1.18, and the Cash Ratio is 1.08.
Transactions by insiders
Recent insider trading involved Barone Francesca, Chief Scientific Officer, that happened on Jan 15 ’25 when 13534.0 shares were sold. Chief Technology Officer, Tyagarajan Seshu completed a deal on Jan 15 ’25 to sell 14322.0 shares. Meanwhile, Schoch Charles sold 9511.0 shares on Jan 15 ’25.
